Skip to main content

Table 2 Cumulative incidence of GVHD

From: Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors

  180-day acute GVHD II–IV 180-day acute GVHD III–IV 2-year chronic GVHD 2-year ext. chronic GVHD
PTCY 28.8% [22.2–35.7] 8.8% [5.1–13.7] 31.4% [23.3–39.8] 18.5% [12–26.1]
ATG 29.2% [26.8–31.6] 9% [7.6–10.6] 33.6% [31–36.2] 13.1% [11.2–15]
pvalue 0.68 0.89 0.43 0.11
  1. Abbreviations: ATG antithymocyte globulin, Ext extensive, GVHD graft-versus host disease, PTCY post-transplantation cyclophosphamide